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Abstract
We used high-resolution mass spectrometry to measure the abundance of more than 9,000 proteins
in 19 individually dissected colorectal tumors representing lymph node metastatic (n=10) and non-
metastatic (n=9) phenotypes. Statistical analysis identified MX1 and several other proteins as
overexpressed in lymph node positive tumors. MX1, IGF1-R and IRF2BP1 showed significantly
different expression in IHC validation (Wilcoxon test p=0.007 for IGF1-R, p=0.04 for IRF2BP1,
and p=0.02 for MX1 at the invasion front) in the validation cohort. Knockout of MX1 by siRNA
in cell cultures and wound healing assays provided additional evidence for the involvement of this
protein in tumor invasion. The collection of identified and quantified proteins to our knowledge is
the largest tumor proteome dataset available at the present. The identified proteins can give
insights in the mechanisms of lymphatic metastasis in CRC and may act as prognostic markers and
therapeutic targets after further prospective validation.
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Introduction
Colorectal cancer is one of the major causes of tumor related death in western countries. The
prognosis becomes worse and 5-year survival rates decrease down to ~60% when lymphatic
metastasis occurs. In recent years post-genomic biology brought about major shift in the
way cancer research is performed. It is expected to eventually lead to mechanistic
elucidation of the disease and to the development of new approaches for early diagnosis and
targeted treatments. The sequencing of human genome and subsequent resequencing of large
number of cancer genomes revealed a complex landscape of driver and passenger mutations
that affect as many as 80 genes in each individual tumor examined, but with only a handful
of less than 15 mutations that occur at statistically significant frequencies1, 2. To make it
more complicated, recent studies suggest that epigenetic alterations might be as important as
mutations in the aetiology of the disease, and that cancer might be a systemic type of disease
that is defined as much by the specifics of the individual organism as by the properties of the
primary tumor and its distant metastases. One of the major challenges facing the modern
post-genomic cancer biology is the elucidation of the complex regulatory mechanisms that
control protein abundance, which very often shows poor correlation with transcript
abundances as comparative studies have demonstrated 3. Genetic mutations and epigenetic
alterations in cancer cells exert their effect most likely by affecting the abundance and the
properties of specific groups of proteins. However the stochastic nature of transcription and
the complex mechanisms that regulate protein synthesis, degradation, and stability
downstream of transcription, make it very difficult to predict how mutations and epigenetic
changes would affect the abundance and the function of relevant proteins.
This study focuses on the proteome as a more direct approach to establish the molecular
hallmarks that distinguish individual tumors and tumors of different stages of the disease,
and which may be utilized to develop better approaches to diagnosis and therapy. We used
the latest generation high-resolution hybrid mass spectrometry to assess the expression of
more than 9000 proteins in a collection of manually dissected colorectal tumors. A subset of
the samples was analyzed in parallel with DNA microarrays. This allowed us to perform
comparative analysis of protein and transcript abundances on a genomic scale and identify
protein candidates that show differential expression in the context of tumor progression from
stage UICC II phenotypes without lymph node metastases to stage UICC III phenotype with
lymph node metasases. Lymphatic metastasis is an independent strong predictor for outcome
in CRC. Therefore for stage UICC III CRC adjuvant chemotherapy is recommended after
surgery. Nevertheless ~30% of these tumors develop recurrent disease which has to be
treated by further chemotherapy, radiation or surgery. Therefore molecular markers are
needed to identify high risk cases and new more effective therapeutic targets. Our findings
provide an insight which transcribed genes will occur as translated and functionally relevant
proteins, and which expressed proteins tend to be more abundant in the metastatic CRC
compared to the non-metastatic tumors.
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Materials and Methods
Patients
Nineteen patients with histopathologically verified primary adenocarcinoma of the
colorectum were included in the study for proteome analysis. From this cohort immediately
after surgery the resected specimens were evaluated by a pathologist and tumor samples
were harvested in liquid nitrogen. The samples were stored at -80°C before further work up.
In a validation cohort comprizing 40 patients with colon carcinomas (stage UICC II: n=20;
stage UICC III: n=20) immunohistochemical (IHC) investigations of the paraffin embedded
tumor samples were performed. Patients that have received radiotherapy or suffering from
hereditary syndromes (e.g. familial adenomatous polyposis, HNPCC) or inflammatory
bowel disease (crohn's disease, colitis ulcerosa) were excluded. After histopathological
staging of the whole removed tumor bearing tissue, the samples were divided in groups
either belonging to tumors with (stage UICC III) or without (stage UICC II) lymph node
metastases. The demographic patient data and detailed histopathological results were
selected from the Erlangen Registry for Colorectal Carcinomas (ERCRC) (Supplemental
tables 1 and 4).
Tissue workup for proteome analysis
The tissue workup was performed by cryotomy after manual dissection (CMD) 4. The
harvested tumor samples were inserted into a cryotube (Roth, Karlsruhe, Germany) and
covered with Tissue-Tek (Zakura, Zoeterwoude, Netherlands). The tissue was immediately
shock frozen in liquid nitrogen. Initially a control slice was dissected from the block and
stained with hematoxylin-eosin (HE) dye. Any identified connective tissue or healthy
mucosa was removed from the Tissue-Tek embedded specimen. On a further control slice,
the purity of the carcinoma tissue was checked again and the procedure repeated. When the
carcinoma portion of the Tissue-Tek embedded specimen was judged to be above 80%
continuous series of 10 slices (40 μm) were dissected and collected in a cryotube. The
dissected slices were immediately shock frozen in liquid nitrogen and stored at -80°C until
proteome analysis.
Reagents
Unless indicated otherwise in the text, chemicals and HPLC solvents were purchased from
Sigma-Aldrich. The highest available grades were used.
Protein extraction, separation, digestion, and preparation of samples for mass
spectrometry—The proteins were extracted from the frozen tumor samples with 2X SDS
sample buffer, reduced, alkylated and separated by gel electrophoresis as previously
described 5. The gel lanes were sliced and digested as described previously 5.
Nano-scale LC-/MS/MS analysis—Protein digests analysis was carried out as described
in Greenwood et al (4). Briefly, electrospray ionization MS was performed on a hybrid
LTQ/Orbitrap Velos instrument (Thermo Fisher, USA) interfaced to a split-less nano-scale
HPLC (Ultimate 3000, Dionex, USA). The peptides were desalted at 1 μl.min-1 on a 2 cm
long, 0.1 mm i.d. trap column packed with 5 μm C18 particles (Dionex, USA). The peptides
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were then eluted from the trap column and separated in a 90-min gradient of 2-30% (v/v)
acetonitrile in 0.1% (v/v) formic acid at a flow rate of 0.3 μl.min-1. The separation column
was a 15 cm long, 0.1 mm i.d. pulled tip packed with 5 μm C18 particles (Nikkyo Technos
Co., Tokyo, Japan). The eluting peptides were ionized by applying 1.75 kV via a liquid
junction interface. The LTQ/Orbitrap Velos was operated in positive ion mode and the
Top20 data-dependent scanning mode was used where the instrument first executes 2 high-
resolution scans at a resolution of 30,000 (at 400 m/z) and then 20 MS/MS scans for the 20
most abundant peptide ions having a charge state > 1. During the high-resolution scans the
Orbitrap analyzer accumulated 106 ions for the maximum of 0.5 s. During MS/MS scans the
LTQ was filled with 5,000 precursor ions for the maximum of 0.1 s. We used normalized
collision energy of 30, minimum signal intensity of 500, activation time of 10 ms and
activation Q of 0.250. A dynamic exclusion to avoid repetitive analysis of abundant peptide
ions was used as follows: after a peptide has been analyzed once its m/z was put in the
exclusion list for 30 seconds. The instrument performed an internal mass calibration by a
lock mass 6. All samples were analyzed at least three times by LC-MS/MS to allow
assessment of reproducibility and statistical analysis.
Data analysis of proteins
MS/MS data were analyzed by CPAS (Computational Proteomics Analysis System) as
described in 5. In addition LC-MS/MS data were also analyzed by MaxQuant and the
Andromeda search engine and label free quantitation was performed as described in 7-9.
Protein abundance was assessed by the spectral counting method and by summing up the
peptide ion intensities as determined by a replicate high-resolution scan in the Orbitrap mass
analyzer.
Statistical analysis
Protein identification data were assessed for significance using the PeptideProphet and
ProteinProphet programs from the Transproteomic pipeline incorporated into CPAS as
described previously 5. The MaxQuant searches were performed as described in Cox et al. 7,
using a reverse database to calculate false discovery rate (FDR). Results from the
Andromeda engine were filtered at both peptide and protein level. In both cases the cutoff
was at 1% FDR.
Identification of differentially expressed proteins was performed in R using the packages
permax 10 and locfdr 11, 12. First, the rank-transformed spectral counts output by MaxQuant
were used to calculate permutation-based test statistics, using permax and the non-
parametric two-sample Wilcoxon test. Then the local false discovery rate (fdr) was
calculated for each protein using locfdr. Protein with local fdr less than 0.15 were selected as
candidates. Similar results were obtained using the R package Significance Analysis of
Microarrays (SAM) package 13-15 in its RNA-seq mode (data not shown).
Validation by immunohistochemical staining
Several proteins selected on the basis of SAM q-values and permax p-values were further
subjected to validation experiments utilizing immunohistochemical staining of paraffin-
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embedded formaldehyde-fixed tissue (FFPE) sections from an independent cohort of colon
carcinoma samples.
IHC validation of selected markers was performed in 20 colon carcinomas with (stage UICC
III) and in 20 cases without (stage UICC II) lymph node metastases. Patient and tumor
details are listed in Supplemental Table 4. After formalin fixation paraffin embedded tumor
samples were made immediately after surgery from the resected specimens. 4 μm slices
were cut, rehydrated with xylol and ethanol. After incubation in target retrival solution
endogen peroxidase was blocked. Primary antibodies were added: DNAJA2 (3A1)
(ab124017, Abcam, UK), DNAJB11 (ab75107, Abcam, UK), IGF1 Receptor (phospho
Y1161) (ab39398, Abcam UK), IRF2BP1 (HPA042164, Sigma-Aldrich, Sweden), M143
(anti-M1), Preparation 11/2005/S417 (Dr. Kochs, University of Freiburg, Germany).
Staining was performed as described elsewhere after adding secondary biotinylated
antibodies and staining reagents 16-19. Marker expression results were counted in % of IHC
positive cells separately for tumor center and invasion front (Table 2).
siRNA-mediated MX1 knockdown, Western blotting and wound-healing assays
MX1 was knocked down in two colorectal cell lines, DLD1 and SW450, using
commercially available siRNA reagent (sc45260, Santa Cruz Biotechnology, CA) with
DharmaFECT transfection reagent (Thermo Fisher) following manufacturer's instructions.
The wound-healing assays were performed as previously described (18). For each
transfection reaction, including controls mock-transfected with reagent only, multiple
replicate wells of a 96-well tissue culture plate were seeded with approximately 5000 cells
and incubated for 3 hours to allow the cells to attach. Wounds were created after 24h by
manually scratching each well with a yellow pipette tip and the plate was then gently
washed with pre-warmed medium to remove detached cells and imaged on a Nikon Ti – E
wild field inverted microscope using scan large image option at 10x magnification. The
plate was then incubated for 24 hours and imaged again. The images were processed by the
NIS Elements software, to calculate wound closure rate (LUNDEBERG et al.,1992) and
determine statistical significance whenever judged necessary. After being imaged the cells
were lysed, separated by SDS-PAGE and transferred to PDVF membrane. Anti- MX1/2/3
(C1) mouse monoclonal antibody (Santa Cruz Biotechnology, sc-166412) was used for
detection of MX1. Imaging was done using Li-Cor infrared Odyssey system.
Results
Quantitative proteome profiling
Figure 1 summarizes the procedures undertaken to quantify the colorectal tumor proteomes
and illustrates the reproducibility and quantitative precision of the label-free quantitation
approach. We analyzed 19 individual tumors to generate the raw dataset for quantitation.
The initial intention was to analyze 10 stage UICC III and 10 stage UICC II tumors but one
of the stage II tumors did not pass quality control because the total amount of the protein
extracted from the tissue sample was too low. Therefore the analyzed cohort consisted of 19
tumor samples. The proteome of each tumor was fractionated into size-resolved fractions,
digested and analyzed by nano-scale liquid chromatography and high-resolution tandem
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mass spectrometry on an LTQ Orbitrap Velos instrument (Fig. 1a). Quantitative accuracy
and reproducibility were assessed by comparing technical replicates (Fig. 1b) and by
comparing the abundance estimates obtained by spectral counts (SpC) and label-free peptide
ion intensities (data not shown). Figure 1b illustrates technical reproducibility of the total
analysis: summed spectral counts for each detected protein from one set of LC-MS/MS runs
analyzing all fractions obtained by electrophoresis were plotted against another set of LC-
MS/MS runs analyzing the same set of samples. In addition, we performed paralleled
quantitative analysis by the accurate isotope dilution method 20, 21. We followed a modified
AQUA procedure that takes advantage of the high-resolution mass analysis enabled by the
LTQ Orbitrap instrument 22. The results for one protein, KCD12, are shown in Fig. 1c.
Similar results were obtained for other proteins such as Stat1 (data not shown). As shown in
Fig. 1b, the technical reproducibility is excellent with coefficient of correlation exceeding
0.99. The absolute amounts of the protein measured by internal labeled standards correlated
very well with the abundance estimates obtained by the spectral counting method (Pearson
r= 0.96, Fig. 1c).
Supplemental Table 2 gives the average numbers of proteins identified in each tumor and in
total for the 19 analyzed tumors. The numbers apply to the processed dataset that was
filtered at 1% FDR at both, protein and peptide level. The heterogeneity of the dataset is
worth noting; the proteomes of individual tumors overlap but each tumor can be
characterized by a unique pattern of protein expression, possibly underscoring the specifics
of the individual cell and molecular evolution that enabled its formation. A core CRC
proteome comprising about 3,000 proteins is detected in all of the tumors. The most
numerous are the proteins involved in metabolic processes (1,909) and biological regulation
(1,267). Soluble, nuclear, and membrane proteins are detected at comparable rate indicating
that the technique we chose to use does not suffer from the well-known bias toward soluble
proteins that affects other approaches relying on multidimensional gel separation.
Stage UICC III vs. stage UICC II comparison and identification of candidate markers for
lymphatic metastasis
Stage UICC III and UICC II tumors showed very similar total number of proteins identified
per individual tumor, total number of tandem mass spectra acquired, and protein abundance
distributions. Statistical analysis performed in R using the packages permax and locfdr, and
the RNA-seq implementation of the SAM package identified a number of proteins as
significantly overexpressed (local fdr<0.15) in the 10 metastatic tumors compared to the 9
non-metastatic tumors. MX1, an interferon gamma-induced antiviral protein, and several
other proteins were further studied by IHC in an independent patients cohort. The
statistically significant candidate proteins identified by the proteomics screen are presented
in Table 1.
Comparative analysis of protein abundance and mRNA expression in 6 colorectal
carcinomas
In a previously published study the mRNA expression of 14,500 genes was assessed in a
cohort of 80 colorectal tumors obtained and dissected by the same protocols we used for
proteome analysis. We therefore searched the available samples from the mRNA profiling
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study and were able to obtain frozen samples from 6 of the tumors. These were included in
the proteome analysis along with 13 additional samples. The obtained protein abundance
data were correlated with the available gene array data. Supplemental Figure 2 shows scatter
plots and the Spearman correlation coefficients of spectral count data (for protein
abundance) and the oligonucleotide array data for the 6 colorectal tumor samples. There is a
positive but modest correlation with mean r=0.43, recapitulating the now well acknowledged
fact that protein abundance is as much, if not more determined by the rate of translation and
by post-transcriptional control mechanisms, than by the abundance of the corresponding
mRNA 3, 23.
MX1 overexpression in stage UICC III compared to stage UICC II colorectal tumors
Among the proteins identified to be overexpressed in stage UICC III tumors is the interferon
gamma induced protein MX1. This result is intriguing since in a recently published study
MX1 was identified to be overexpressed in metastatic triple-negative breast cancer.
Therefore we carried out additional statistical analyses to evaluate whether MX1 could be
considered as a marker for lymphatic metastasis of colorectal tumors as well. Figure 2 shows
analysis of MX1 abundance in all the 19 tumors analyzed in this study. The box plot in
Fig3a shows spectral count data indicating overexpression in stage III tumors. An alternative
quantitation approach, a measurement based on integrated and summed up peptide ion
intensities further corroborates this conclusion and is presented in Fig3b. In this analysis
Mx1 abundance was assessed on the basis of the signal intensities generated by the peptide
ions corresponding to each of the many identified MX1 peptides.
Validation by immunohistochemistry and follow-up mechanistic cell culture studies
In the next stage of the study several candidate proteins were subjected to validation by
orthogonal experimental approaches. The results from these validation and mechanistic
experiments are summarized in Table 2, and Figures 3 and 4. Three proteins were positively
validated by immunohistochemistry in an independent cohort of samples from 20 stage
UICC III and 20 stage UICC II patients. These were MX1 and IGF1-R, found to be
overexpressed particularly at the invasion front of stage UICC III tumors, and IRF2BP1,
found to be significantly decreased in stage UICC III in both, tumor centers and invasion
fronts compared to UICC stage II tumors.
In addition to the validation experiments utilizing antibody-based staining of tumor tissue,
we undertook to evaluate the potential involvement of MX1 in tumor cells' migration and
invasion. To this end we knocked-down the expression of MX1 in 2 colorectal cancer cell
lines using MX1-specific siRNA and carried out wound-healing assays. The results, shown
in Figure 4 clearly demonstrate that MX1 knock-down strongly inhibits wound healing of
DLD1 cells. The second cell line, SW480, was also affected but to a lesser extent, although
the results were highly reproducible (data not shown). This could possibly be explained by
the facts that SW480 were not as migratory as DLD1 and also, the knock-down of MX1 was
not as efficient as in DLD1 as shown on the western blot in Figure 4.
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Discussion
The sequencing of the human genome and the development of high-throughput technologies
that allow the activities of thousands of genes to be assayed simultaneously, and in only a
minute amount of clinical sample, enabled a plethora of new approaches that can be used for
identification and validation of biomarkers and drug target candidates in oncology. In
particular, it is now possible to not only map the entire landscape of genomic mutations in
individual tumors, but also, using array technologies or next-generation sequencing, to
measure the activity of the tumor genome in a highly quantitative and comprehensive
way 1, 24, 25. These new capabilities are expected to enable a new and more efficient
personalized approach to treating cancer and other diseases. However, one important
shortcoming of clinical genomics cannot be overlooked: many proteins that are key players
in cancer biology are known to be regulated at post-transcriptional level. Such proteins will
slip through any mutation and gene expression screen and remain undetected as causative
agents or biomarkers because our knowledge of the regulation of protein abundance in the
cell is far from complete. Thus, if we were to base our attempts to develop personalized
cancer treatments solely on mutation and gene expression data, these attempts are destined
to fail, or at best, to deliver very modest results. Therefore genomics needs to be
complemented with protein level analysis for both, drug target identification and
development of novel diagnostic assays.
Here we applied recently developed mass spectrometry-based techniques that can be used to
acquire an almost genome-scale quantitative snapshot of protein abundance in tumors. Such
data could be extremely useful and complementary to genomics in a number of ways: it can
provide validation of candidate genes, it can lead to the identification of likely drug targets
that are overexpressed in a subset of tumors due to post-transcriptional mechanisms, it can
provide candidate proteins for the development of new types of multiplex diagnostics with
increased specificity and sensitivity.
We used a recently developed hybrid high-resolution mass spectrometry technology 26 to
analyze 19 colorectal tumors grouped by stage into metastatic (stage UICC III) and non-
metastatic (stage UICC II) classes. The tumor tissue was manually dissected to ensure tumor
enrichment, homogeneity and to maximize the coverage of the proteome analysis. As a
result we achieved an analytical depth of more than 9,000 proteins identified in the 19 tumor
samples, to our knowledge the largest tumor proteome data set to date. The proteins
abundance was estimated by spectral counting and by label-free intensity methods. In the
subsequent analyses we used protein spectral counts to identify differentially expressed
proteins because of the robustness and reproducibility of this approach and its applicability
to unlabeled clinical samples 5, 22, 27. This led to the identification of several proteins that
were significantly overexpressed in the stage UICC III tumors compared to the non-
metastatic stage UICC II tumors (Table 1). Among the proteins pinpointed as significant
three proteins were selected for further validation. These were MX1, a GTP-binding protein
involved in antiviral responses28, 29, IGF1-R a growth factor receptor known to be involved
in cancer (reviewed in 30) and IRF2BP1, a protein involved in the regulation of interferon-
induced gene expression31. The identification of MX1 as the top proteomic candidate
marker for distinguishing between the stage UICC III and stage UICC II tumors in the
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analyzed cohort is intriguing because of its apparent involvement in antiviral responses and
also, because we recently identified this protein to be among the proteins that are
overexpressed in metastatic triple-negative breast cancer 22. To further investigate this we
performed wound-healing experiments, which confirmed the possible involvement of MX1
in colorectal tumor cells' invasion and metastasis (Fig. 5). Validation by
immunohistochemical methods provided further evidences in this direction (Fig. 4 and Table
2).
Concluding remarks
In this study we have achieved 9,000+ proteins coverage of the colorectal tumor proteome,
which led to the identification of candidate markers of lymphatic metastasis. Simultaneous
measurement of mRNA and proteins abundances in 6 tumors showed that the correlation
between protein and message abundances is about 40%, which suggests that tumor genomics
should always be complemented with paired proteome analysis. Furthermore, the
quantitative atlas of protein abundance in colorectal tumor generated by this study can be
explored in the future to identify and/or validate candidate drug targets and diagnostic
markers, and to identify molecular pathways that contribute to tumor invasion and
metastasis. An example of such candidate marker/target is MX1 which was the top
candidate selected by proteomics, and was successfully validated in an independent cohort
of samples and in cell-based mechanistic studies utilizing siRNA-mediated knock-down and
wound-healing assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty and impact
We report very large-scale proteome analysis of 19 colorectal tumors. More than 9,000
proteins were identified, which makes the generated dataset the largest colorectal tumor
proteome to date. The study identified candidate biomarkers for metastasis. Three of the
proteins, MX1, IGF1-R, and IRF2BP1, were further validated in an independent cohort
of 40 tumor samples and MX1 was also studied in knockout experiments using small
interfering RNA.
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Figure 1.
Large-scale analysis of protein abundance in manually-dissected colorectal tumors. a: A
workflow diagram illustrating the individual steps of the analysis. Proteins are extracted,
fractionated by PAGE, digested and analyzed by nano-scale LC-MS/MS on a hybrid high-
resolution LTQ/Orbitrap Velos instrument. The individual proteins are then quantified by
label-free techniques. Altogether we performed more than 300 individual LC-MS/MS runs
to analyze the 19 tumor specimens. b: Scatter plot comparing data from 2 technical replicate
analyses. The R-squared is shown on the plot. c: Validation of the spectral count data by a
modified AQUA assay. A labeled peptide derived from KCD12 was spiked into the protein
digests and used as an internal standard to quantify the endogenous KCD12.
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Figure 2.
Quantitation of MX1 in 19 colorectal tumors by two label-free approaches. A: MX1 was
quantified by spectral counting. B: Quantitation was done by label-free peptide intensities
integration. In both analyses the non-parametric Mann-Whitney t-test was used to assess if
the means are significantly different between stage UICC III and stage UICC II tumors.
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Figure 3.
Validation of candidate proteins by IHC. A: Representative IHC staining of MX1 in stage
UICC III and stage UICC II tumors. B: Boxplots for MX1, IGF1-R, and IRF2BP1. The p
values calculated by the two-sample Wilcoxon test are indicated for the significant proteins.
The validation cohort comprised 20 stage UICC III samples and 20 stage UICC II samples.
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Figure 4.
MX1 Knock-down and wound-healing assays with DLD1 cells. A: Wound-healing assays
with cells transfected with MX1-specific siRNA or mock-transfected. B: Western blotting
analysis of lysates from control and MX1 knock-down DLD1 and SW480 cells. MX1 and
tubulin bands are indicated with arrows.
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Table 1
Analysis of protein expression in Stage III against stage II in colorectal tumors by permax and locfdr. The
protein spectral counts assigned at 1% false discovery rate (fdr) by MaxQuant at both, peptide and protein
level were used to perform the calculations. Local fdr was calculated in R using the package locfdr and the
two-sample Wilcoxon test statistics calculated by permax. The individual one-sided p values in the table are
based on the two-sample Wilcoxon statistics.
Gene IPI Wilcoxon p Local fdr
MX1 IPI00167949 —4.55 0.00003 0.0002
DNAJA2 IPI00032406 —4.18 0.000014 0.0012
CASP7 IPI00216675 —3.57 0.000178 0.0180
DNAJB11 IPI00008454 —3.57 0.000180 0.0182
GOLPH3L IPI00514951 —3.39 0.000350 0.0340
AIP IPI00925804 —3.07 0.001081 0.0885
IGF1R IPI00027232 —3.07 0.001081 0.0889
RNF4 0 IPI00162563 —3.07 0.001081 0.0889
CDC27 IPI00794278 —3.07 0.001081 0.0889
CLN5 IPI00026050 —2.99 0.001389 0.1076
TTC1 IPI00016912 —2.92 0.001776 0.1294
HAT1 IPI00024719 —2.92 0.001776 0.1294
UBAC1 IPI00305442 —2.92 0.001776 0.1294
NUDC IPI00550746 —2.92 0.001776 0.1294
OLA1 IPI00916847 —2.92 0.001776 0.1294
COX7A2L IPI00022421 3.22 0.000635 0.1346
PMPCA IPI00166749 3.22 0.000635 0.1346
GLS IPI00289159 3.22 0.000635 0.1346
CASP2 IPI00291570 3.22 0.000635 0.1346
IRF2BP1 IPI00645608 3.22 0.000635 0.1346
HSPB6 IPI00908768 3.22 0.000635 0.1346
FRMD8 IPI00011090 3.39 0.000350 0.0823
ALDH5A1 IPI00336008 3.39 0.000350 0.0823
NT5DC2 IPI00783118 3.39 0.000350 0.0823
RPL14 IPI00555744 3.76 0.000086 0.0211
MRPS33 IPI01010059 3.96 0.000037 0.0083
DAG1 IPI00028911 4.18 0.000014 0.0031
CCDC93 IPI00154668 4.18 0.000014 0.0031
MESDC2 IPI00399089 4.18 0.000014 0.0031
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Table 2
Expression of markers in the tumor center and invasion front detected by immunohistochemistry, stage UICC
II: lymph node negative colon carcinomas, stage UICC III: lymph node positive colon carcinomas, values are
presented as percent positive tumor cells. The p value is calculated by the two-sample Wilcoxon test.
Significant proteins are shown in bold.
UICC II Mean (median); % UICC III Mean (median); % p
Tumor center
IGF1-R 79 (85) 82 (80) 0.42
MX1 13 (5) 17 (17) 0.19
DNAJA2 92(95) 87 (95) 0.76
IRF2BP1 69 (75) 17 (0) 0.008
DNAJB11 78 (90) 69 (80) 0.47
Invasion front
IGF1-R 84 (90) 89 (90) 0.007
MX1 24 (7.5) 46 (47.5) 0.02
DNAJA2 93 (95) 86 (90) 0.12
IRF2BP1 62 (80) 37 (0) 0.04
DNAJB11 81 (90) 83 (80) 0.60
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